The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2021 | Phase 1 trials of novel CAR T-cells for leukemia
Sarah K. Tasian, MD, University of Pennsylvania School of Medicine and Abramson Cancer Center, Philadelphia, PA, gives an overview of Phase I clinical trials of chimeric antigen receptor (CAR) T-cells for leukemia at AACR 2021. Dr Tasian discusses the use of CD33-targeted CAR T-cells for the treatment of acute myeloid leukemia (AML) in children, adolescents and young adults. Dr Tasian also outlines preclinical development of FLT3-directed CAR T-cells for FLT3 mutant AML and KMT2a-rearranged acute lymphoblastic leukemia (ALL), and a first-in-human trial of thymic stromal lymphopoietin receptor (TSLPR) CAR T-cells for CRLF2-rearranged Philadelphia chromosome-like ALL. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Sarah K. Tasian, MD, has received research funding from Incyte Corporation, and has participated in scientific advisory boards for Kura Oncology and Aleta Biotherapeutics.
